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7RESEARCH ARTICLE Open AccessEvaluation of the Hepa Wash® treatment in pigs
with acute liver failure
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Zejian Yang1, Catherine Schreiber6, Patrick Schimmel6, Ewald Nairz6, Aurel Perren8,9, Peter Radermacher10,
Wolfgang Huber1, Roland M Schmid1 and Bernhard Kreymann1,6Abstract
Background: Mortality of patients with acute liver failure (ALF) is still unacceptably high. Available liver support
systems are still of limited success at improving survival. A new type of albumin dialysis, the Hepa Wash® system,
was newly introduced. We evaluated the new liver support system as well as the Molecular Adsorbent Recycling
System (MARS) in an ischemic porcine model of ALF.
Methods: In the first study animals were randomly allocated to control (n=5) and Hepa Wash (n=6) groups. In a
further pilot study, two animals were treated with the MARS-system. All animals received the same medical and
surgical procedures. An intraparenchymal intracranial pressure was inserted. Hemodynamic monitoring and goal-
directed fluid therapy using the PiCCO system was done. Animals underwent functional end-to-side portacaval
shunt and ligation of hepatic arteries. Treatment with albumin dialysis was started after fall of cerebral perfusion
pressure to 45 mmHg and continued for 8 h.
Results: All animals in the Hepa Wash group survived the 13-hour observation period, except for one that died
after stopping treatment. Four of the control animals died within this period (p=0.03). Hepa Wash significantly
reduced impairment of cerebral perfusion pressure (23±2 vs. 10±3 mmHg, p=0.006) and mean arterial pressure (37±1 vs.
24±2 mmHg, p=0.006) but had no effect on intracranial pressure (14±1 vs. 15±1 mmHg, p=0.72). Hepa Wash also
enhanced cardiac index (4.94±0.32 vs. 3.36±0.25 l/min/m2, p=0.006) and renal function (urine production, 1850 ± 570 vs.
420 ± 180 ml, p=0.045) and eliminated water soluble (creatinine, 1.3±0.2 vs. 3.2±0.3 mg/dl, p=0.01; ammonia 562±124 vs.
1382±92 μg/dl, p=0.006) and protein-bound toxins (nitrate/nitrite 5.54±1.57 vs. 49.82±13.27 μmol/l, p=0.01). No adverse
events that could be attributed to the Hepa Wash treatment were observed.
Conclusions: Hepa Wash was a safe procedure and improved multiorgan system failure in pigs with ALF. The survival
benefit could be the result of ameliorating different organ functions in association with the detoxification capacity of
water soluble and protein-bound toxins.
Keywords: Artificial liver, Acute liver failure, Albumin dialysis, Animal model, Swine, Renal dialysis, Multiple organ failure,
Capillary leak syndrome, Cardiovascular failure, Renal failureBackground
Since the introduction of renal replacement therapy, dif-
ferent methods of extracorporeal liver support therapies
were tested. They appear to improve the survival of pa-
tients with acute liver failure but didn’t have a major im-
pact on survival of patients acute-on-chronic liver failure* Correspondence: ahmed.alchalabi@gmail.com
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reproduction in any medium, provided the or[1]. The mortality of liver failure remains unacceptably
high and liver transplantation is still the only effective
treatment. Albumin dialysis is one of the latest therapeutic
approaches introduced. To date there are two types of al-
bumin dialysis: Single Pass Albumin Dialysis (SPAD) and
Molecular Adsorbent Recycling System (MARS®). The
former has been described mainly in sporadic cases, where
its use is limited by the costs of albumin and efficacy
[2-6]. MARS has been used more widely and it has been
shown to be effective in improving biochemical profiletral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patient groups [7-9]. A hard evidence of survival benefit
of the MARS procedure is however still lacking, as the
results of a large multicenter study have shown no im-
provement of mortality in patients with fulminant and
subfulminant liver failure [10]. Different bioartificial liver
support systems were used enthusiastically in small clin-
ical trials [11-13] but in a multicenter study conducted by
Demetrieu et al., they were found to improve the survival
of patients with fulminant/subfulminant liver failure only
after excluding primary nonfunction following liver trans-
plantation which was included in the study group [14].
Finally, extracorporeal therapy with fractionated plasma
Separation and Adsorption (Prometheus®) was associated
with an improved survival in patients with acute liver fail-
ure, but mainly in retrospective and case report studies
[15-17].
Animal models simulating acute liver failure (ALF) are
not only needed to study the underlying poorly under-
stood pathophysiological mechanisms but are also im-
portant for the evaluation of new liver support systems
prior to introduction in clinical studies. Devascularizing
ALF is one of the most common animal models used for
evaluating liver support systems. Recently, our group de-
veloped such a model and tested its reproducibility [18].
In this work we present a preclinical study that evalu-
ates the safety and efficacy of a new liver support system
(Hepa Wash®, Figure 1), a type of albumin dialysis, in a
large animal model of ischemic ALF. We also present
the results of the MARS treatment in two pilot animals
of the same model.
Methods
Animals and housing
The preclinical study was approved by the ethical commit-
tee for animal studies in Bavaria, Germany. German land-
race female pigs (~60 kg) were procured from the animalFigure 1 A schematic representation of Hepa Wash. The new liver supp
Hepa Wash circuits.farm and were kept in the animal housing in the center for
preclinical research in the hospital rechts der Isar for about
4–7 days to allow for accommodation. Animals were fasted
approximately twelve hours before the operation but had
free access to water. Housing and all medical and surgical
procedures (Figure 2) were in accordance with the national
animal protection act (Tierschutzgesetz) and the institution
guidelines (registration number 55.2-1-54-2531-60-07, ap-
proved on 20.6.2007). Experiments were performed be-
tween January and April 2008. The Animals were divided
randomly into two groups: the control (n=6) and the Hepa
Wash (n=6) groups. One animal in control group was ex-
cluded due to insufficient induction of liver failure (which
was histopathologically confirmed).
In a small pilot study (n=2) that was conducted inde-
pendently from the above randomized study, animals
with acute liver failure were treated by the Molecular
Adsorbent Recirculating System (MARS).
All animals in the Hepa Wash and the control groups
and the two animals in the MARS pilot study were
subjected to the same following surgical and medical
procedures and all were treated under the same condi-
tions e.g. noise.
Anesthesia and ventilation
Premedication of the animals was performed with keta-
mine (15 mg/kg), azaperone (2 mg/kg) and atropine
(0.5-1 mg/kg) intramuscularly, respectively. Induction of
anesthesia with propofol (60–100 mg, i.v.) was followed
by intubation. Anesthesia was maintained intravenously
with propofol (up to 8.5 mg/kg/h) fentanyl (up to 0.015
mg/kg/h), and atracurium (up to 0.7 mg/kg/h) depend-
ing on the depth of anesthesia. Animals were venti-
lated (Cicero EM, Dräger Medical Deutschland GmbH,
Lübeck, Germany) with intermittent positive pressure
and a mixture of oxygen and air (FiO2 30-60%). Mean
airway pressure was aimed below 30 cmH2O and I:Eort system is composed of three circuits: the blood, dialysate and
CPP=45 
mmHg
Induction of ALFAdmission 
to theatre
Surgical procedures
Euthanasia of 
surviving animals
T0 T13
Hepa Washtreatment (8h) /
Medical treatment 
Individualized starting 
point for treatment
T4 T8 T12
Figure 2 A timeline of the experiments.
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http://www.biomedcentral.com/1471-230X/13/83ratio was adjusted to 1:2. The ventilation rate and tidal
volume were set between 14–20 breaths per minute and
6–10 ml/kg, respectively, to ensure proper oxygenation.
Adequacy of anesthesia was assessed clinically by ob-
serving the animals ensuring that they have sufficient
relaxation and analgesia. Spontaneous breathing must
be absent.Cannulation
Prior to induction of ALF, two jugular veins were cannu-
lated to facilitate fluid and drug infusions. Blood arterial
pressure was measured invasively using a cannula in-
serted into the carotid artery. A dialysis catheter (13F
high flow two-lumen 20 cm, Achim Schulz-Lauterbach
VMP, Iserlohn, Germany) was inserted so that the tip is
in the right atrium of the heart. The femoral artery was
catheterized with a 5-French thermistor-tipped catheter
(PV 2015L20, Pulsion Medical Systems AG, Munich,
Germany). A surgically inserted suprapubic bladder
catheter was used to collect urine. An intracranial pres-
sure transducer, Neurovent-P Temp (Raumedic AG,
Helmbrechts, Germany) was inserted and positioned in
the cerebral parenchyma.Establishment of ALF
The surgical anatomy and procedures were described in
more detail previously [18]. Laparotomy was performed
and the structures in the hepatoduodenal ligament were
exposed. The portal vein and inferior (caudal) vena cava
were then partially clamped before a functional end-to-
side portacaval shunt was established with polypropylene
(prolene®, Ethicon Inc., Norderstedt, Germany). The de-
velopment of splanchnic congestion was avoided by en-
suring an adequate portal flow during partial clamping.
All arteries supplying the liver and the hepatoduodenal
ligament (except for bile duct which was left intact) were
ligated (Vicryl® 2/0, Ethicon Inc., Norderstedt, Germany).
Cefuroxime 500 mg was administered as an infusion
during surgery.Acid–base household and electrolytes
Sodium bicarbonate administration (8.4%) was adminis-
tered to treat metabolic and respiratory acidosis if
pH<7.3 or to increase bicarbonate levels (aim 28–30
mmol/l). Hyperkalemia was treated by insulin injections
(5–25 IU) in boluses with simultaneous adjustment of
glucose infusions. We used potassium-containing solu-
tions or added KCl (20–80 ml, 1M) to the glucose infu-
sions to correct hypokalemia. Hypocalcemia was treated
by infusing calcium gluconate 10% 10-100ml/h.Fluid therapy
Infusion of crystalloids (saline, glucose 5% or 20%) was
directed according to measurements of the PiCCO sys-
tem (Pulsion Medical Systems AG, Munich, Germany).
Aim was to keep extravascular lung water index (ELWI)
<12 ml/kg and global end-diastolic volume index (GEDI)
between 500 and 800 ml/m2 as possible. The choice of
crystalloids was dependent on the electrolyte balance, glu-
cose level and acid–base balance. We targeted a mean
blood glucose level of around 120 mg/dl [19].Albumin dialysis
A laboratory prototype (Hepa Wash GmbH, München,
Germany) was used to conduct the the Hepa Wash
treatments. It is composed of three circuits: the blood,
dialysate and Hepa Wash circuits (Figure 1). Approxi-
mately 40 grams of human serum albumin were used for
each treatment. The composition of albumin dialysate in
the hemodialyzers is similar to that of dialysate used in con-
ventional hemodialysis (apart from containing 2% albumin).
Postdilution 2l/h was performed with PrismaSol2® (Gambro
Hospal GmbH, Gröbenzell, Germany). In the Hepa Wash
circuit, albumin dialysate is divided into two parts. Each
part undergoes a change of pH value by adding acid or base
before passing through the filters resulting in a release of
albumin-bound toxins. The unbound portion of toxins is
removed by a filtration process. The acidified and the
alkalinized albumin dialysates join each other so that a
Figure 3 Hepa Wash significantly ameliorated cerebral
perfusion pressure (CPP). * p<0.05 (difference between Hepa
Wash and control); ** p=0.006 (difference between Hepa Wash and
control); † Death of animals; SEM: standard error of mean.
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in the dialysate compartment of the hemodialyzers.
The treatment sessions in the two animals treated with
MARS were performed independently by the Hepanet
GmbH, Hannover, an established provider of the MARS
therapy. The system was filled with 100g albumin.
Heparin was given to all animals (including the control
group) by continuous infusion. Anticoagulation was moni-
tored through the activated clotting time (ACT), which
was measured by the Hemochron® (ITC, Edison, NJ). The
ACT was kept between 150–250 seconds.
Both Hepa Wash and MARS were started as soon as
the cerebral perfusion pressure dropped to 45 mmHg
and were all continued for 8 hours.
Sampling
Blood gas analysis was performed frequently to ensure
optimal and quick adjustment of certain parameters e.g.
glucose (Rapidpoint® 405, Siemens Health Care Diagnos-
tics Inc., Eschborn, Germany). Blood samples were col-
lected immediately before induction of ALF (T0) and
every two hours thereafter. Samples for the measure-
ment of nitrate/nitrite blood levels were frozen at −80°C
and analyzed using the chemiluminescence method.
Euthanasia and autopsy
Surviving animals were sacrificed with a lethal dose of
pentobarbitone and KCl injected intravenously 13 hours
after induction of ALF. Animals were considered dead if
cerebral perfusion pressure ≤ 5 mmHg for 5 minutes.
All animals were examined for signs of bleeding during
autopsy.
Statistics
For comparing Hepa Wash with the control group, we
used the cerebral perfusion pressure as the primary end
point. The “ordered” hypotheses method was employed
to avoid correction for the multiplicity of alpha error
when multiple comparisons are performed [20]. If some
of the data especially at the end of the experiments were
missing due to death of the animal, then they were as-
sumed to be equal to the latest measured value (the last
value carried forward method). Data were expressed as
mean ± SEM (standard error of the mean) - unless stated
otherwise (as median and range) - after handling of the
missing data. Comparisons were carried out as follows:
The data were compared first from the latest time point i.e.
eight hours after decrease of cerebral perfusion pressure to
45 mmHg. If the null hypothesis (no difference of cerebral
perfusion pressure between the two groups) was rejected,
an earlier adjacent time point was analyzed. Comparisons
are repeated for the time points going backwards until the
values are not significant anymore. Further statistical data,
graphs and p-values for other parameters including theresults of MARS treatments were displayed for explorative
purposes only and not to be taken as confirmatory
evidence.
Data were documented and analyzed using IBM SPSS
19.0 for Windows®. A non-parametric test (Mann–Whitney
U) was used to compare the readings and biochemical
values between groups, whereas the log-rank test was
employed to statistically evaluate survival differences. A
two-tailed p-value less than 0.05 was considered to indicate
statistical significance.
Results
Cerebral parameters
The cerebral perfusion pressure decreased to 45 mmHg
after a median of 3¾ h (2-5 h) in the Hepa Wash group,
and after a median of 3¼ h (2-4½ h) in the control group
from induction of liver failure (p=0.46). The cerebral
perfusion pressure was significantly higher after 8 hours
of treatment in the Hepa Wash group in comparison
with the control group (23 ± 2 vs. 10 ± 3 mmHg, re-
spectively, p=0.006) (Figure 3). A significant difference
was found as early as five hours after reduction of cere-
bral perfusion pressure to 45 mmHg (p=0.045). In con-
trast, the intracranial pressure did not change significantly
after 8 hours of treatment with Hepa Wash (14 ± 1 vs.
15 ± 1 mmHg, respectively, p=0.72) (Table 1).
Survival
Four animals in the control group died during the obser-
vation period with a median of 10¾ h (9-13 h) (Figure 4).
Five animals in the Hepa Wash group survived the 13-
hour observation period. Only one animal died in the
Hepa Wash group, and this occurred shortly after the
end of the 8-hour-treatment period with Hepa Wash.
Table 1 List of the main hemodynamic parameters of animals in the control and Hepa Wash groups
Time [h] T0 T4 T8 T12
Group Controls (n=5) Hepa Wash
(n=6)
MARS (n=2) Control (n=5) Hepa Wash
(n=6)
MARS (n=2) Control (n=5) Hepa Wash
(n=6)
MARS (n=2) Control (n=2) Hepa Wash
(n=6)
MARS (n=1)
Cerebral perfusion
pressure [mmHg]
87 ± 10 90 ± 4 84, 70 40 ± 3 46 ± 3 35, 36 24 ± 1 34 ± 2* 21, 34 18, 6 22 ± 1* 10
Cardiac index
[l/min/m2]
5.06 ± 0.30 5.13 ± 0.37 4.01, 4.5 5.15 ± 0.58 5.66 ± 0.50 5.65, 6.1 3.96 ± 0.17 5.36 ± 0.38* 5.37, 5.71 3.58, 2.51 4.94 ± 0.33* -
ELWI [ml/kg] 8±1 7±1 6, 7 9±0 8±1 8, 7 9±1 7±1 7, 7 8, 13 8±1 -
GEDI [ml/m2] 598±28 620±31 578, 609 571±53 619±44 602, 579 524±58 626±28 653, 638 489, 476 622±41 -
SVRI
[dyn.s.m2.cm-5]
1291±45 1361±200 1080, 1307 887±66 874±85 670, 660 815±69 741±71 539, 576 570, 762 607±49 -
Mean Arterial
Pressure [mmHg]
96±9 99±4 93, 79 49±3 56±3 47, 46 38±2 48±1* 36, 48 29, 22 36±1* 34
Intracranial
Pressure [mmHg]
9.3±0.8 9.1±0.9 8.2, 9.1 9.1±0.8 10.4±1.1 12.3, 10.4 13.6±1.9 13.9±2.3 14.7, 13.7 11.4, 16.4 13.9±0.8 24.4
Intracranial
temperature [°C]
36.8±0.3 37.0±0.2 38, 37.9 36.9±0.2 37.4±0.3 37.6, 37.7 37.2±0.2 36.9±0.1 37.6, 37,3 36.5, 36.6 36.9±0.2 36.0
ELWI: extravascular lung water index. GEDI: global enddiastolic volume index. SVRI: systemic vascular resistance index.*p<0.05 (difference between Hepa Wash and control).
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Figure 5 Elimination of ammonia by the Hepa Wash procedure.
* p<0.05 (difference between Hepa Wash and control); † Death of
animals; SEM: standard error of mean.
Figure 4 A cumulative survival analysis showing an
improvement of survival with the Hepa Wash procedure.
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http://www.biomedcentral.com/1471-230X/13/83The corresponding log-rank test showed a significant
survival improvement in the Hepa Wash group (p=0.03).
In contrast, the two animals in the MARS group sur-
vived for approximately 11½ and 12 h, respectively, after
the induction of the liver failure. Deat h occurred after
stopping treatment but also after a dramatic elevation of
intracranial pressure shortly before end.
Liver failure
Animals in the Hepa Wash and control groups showed
signs of fulminant hepatic failure with a rapid worsening
of Quick value (prothrombin time) (39 ± 4 vs. 33 ± 5% at
T 12, respectively, p=0.71) and INR (2.0 ± 0.1 vs. 2.7 ± 0.8
at T12, respectively, p=0.57). Fibrinogen also decreased
rapidly (218 ± 18 vs. 233 ± 54 mg/dl at T12, respectively,
p=0.71).
Hemodynamics
The mean arterial pressure in the Hepa Wash group was
higher than in the control group (37 ± 1 vs. 24 ± 2 mmHg,
respectively, p=0.006) after 8 hours of treatment (i.e. eight
hours after cerebral perfusion pressure reached 45 mmHg)
(Figure 3). The difference started to be significant after
4 hours of treatment (p=0.045) (Figure 3). The cardiac
index was also higher in the Hepa Wash group at T12
(4.94 ± 0.33 vs. 3.36 ± 0.25, p=0.006). (Table 1). GEDI and
ELWI were not significantly different between the two
groups (Table 1). There was a positive fluid balance of
around 230 ± 35 ml/h in the control group, whereas it
was 320 ± 100 ml/h in the Hepa Wash group (p=0.46).
Urine output
Animals in the Hepa Wash group produced more urine
(1850 ± 570 ml) than in the control group (420 ± 180 ml),collected after cerebral perfusion pressure decreased to
45 mmHg (p = 0.045).
Detoxification
Creatinine and blood urea nitrogen (BUN) were signifi-
cantly lower in the Hepa Wash group than in the control
group at T12 (1.3 ± 0.2 vs. 3.2 ± 0.3, p=0.01 and 5 ± 0 vs.
10 ± 1, p=0.006, respectively). Ammonia (Figure 5) was
effectively removed from the blood of the animals in the
Hepa Wash group (562 ± 124 vs. 1382 ± 92 μg/dl, at T12,
p=0.006). Nitrate/nitrite levels were similarly lower in the
Hepa Wash group (5.54 ± 1.57 vs. 49.82 ± 13.27 μmol/l
at T12, p=0.01). Significant differences between the Hepa
Wash and the control groups were found for blood pH
and glucose (Table 2).
Safety of Hepa Wash procedure
No significant differences were seen between the two
groups for platelets or other coagulation parameters like
antithrombin-III (Table 2). Despite anticoagulation with
heparin in both groups no purpural skin lesions or in-
ternal hemorrhage was observed during autopsy.
Discussion
This preclinical study evaluated a new type of albumin
dialysis, the Hepa Wash procedure. The extracorporeal
procedure was used for the first time in the treatment of
pigs with ALF. The ischemic model used in this study
was described in a previous work [18] and has a rela-
tively large therapeutic window with less pronounced
elevation of intracranial pressure in comparison with
other surgical models used to evaluate other liver support
systems, where the animals were smaller in size and the
portal vein diversion was established by an end-to-side
portacaval shunt [21-24]. Avoiding splanchnic congestion
Table 2 List of the main biochemical and hematological parameters of animals in the control and Hepa Wash groups
Time [h] T0 T4 T8 T12
Group Controls (n=5) Hepa Wash
(n=6)
MARS (n=2) Control (n=5) Hepa Wash
(n=6)
MARS (n=2) Control (n=5) Hepa Wash
(n=6)
MARS (n=2) Control (n=2) Hepa Wash
(n=6)
Blood pH 7.41±0.02 7.42±0.02 7.44, 7.41 7.35±0.03 7.41±0.02 7.35, 7.34 7.33±0.02 7.44±0.02* 7.36,7.33 7.27, 7.30 7.42±0.01*
Sodium [mmol/l] 136±1 136±1 133, 136 137±1 138±2 132, 134 134±1 143±2* 130, 130 138, 133 142±2*
Potassium [mmol/l] 4.3±0.1 4.4±0.2 4.9, 4.3 4.4±0.2 4.5±0.3 5.1, 4.23 4.8±0.2 4.0±0.2 4.9, 5.2 5.4, 5.7 4.4±0.3
Glucose [mg/dl] 98±9 112 ± 8 95, 107 111±14 109±10 143, 135 154±48 106±3 102, 145 120, 127 97±6*
ALP [U/l] 130±12 128 ± 8 181, 101 199±12 187±13 277, 136 279±12 253±11 382, 226 304, 326 323±14
GPT [U/l] 27 ± 2 36 ± 2 37, 39 74 ± 15 152 ± 42 184, 83 111 ± 15 213 ± 26* 201, 226 128, 108 222 ± 19*
GOT [U/l] 29 ± 1 33 ± 4 17,28 962 ± 263 2607 ± 884 3086, 1179 1977 ± 348 4076 ± 446* 3464, 5593 2024, 2254 4250 ± 282*
Total protein [g/dl] 5.4±0.3 5.3 ± 0.2 5.8, 5.6 5.2±0.3 5.2±0.1 5.2, 5.0 4.8±0.4 5.2±0.2 5.1, 4.9 4.3, 3.5 4.9±0.3
Total Bilirubin
[mg/dl]
0.2±0.0 0.2±0.0 0.3, 0.2 0.6±0.1 0.5±0.1 0.7, 0.3 0.8±0.2 0.5±0.1 0.9, 0.5 1.0, 0.5 0.6±0.0
BUN [mg/dl] 9±1 9±1 11, 11 9±1 7±1 11, 9 9±1 5±0* 10, 10 8, 9 5±0.3*
Creatinine [mg/dl] 1.3 ± 0.1 1.3 ± 0.1 1.3, 1.1 1.4 ± 0.1 1.2 ± 0.1 1.5, 1.2 2.2 ± 0.1 1.0 ± 0.0* 2.1, 1.6 3.5, 3.5 1.3 ± 0.2*
Ammonia [μg/dl] 201 ± 31 178 ± 18 168, 235 514 ± 69 535 ± 61 734, 820 977 ± 193 454 ± 102 1072, 1077 1395,1268 562 ± 124*
Lactate [mmol/l] 2.0±0.1 1.6±0.1 1.2, 1.2 2.5±0.4 2.4±0.4 2.2, 1.6 1.9±0.1 1.9±0.2 1.5, 1.5 2.5, 3.5 2.5±0.4
INR 0.9±0.0 1.0±0.0 0.9, 0.9 1.2±0.1 1.3±0.1 1.1, 1.1 2.0±0.5 1.7±0.2 1.4, 1.9 1.7, 1.9 2.0±0.1
Fibrinogen [mg/dl] 425±77 456±18 513, 507 393±69 348±32 377, 372 303±71 262±21 290, 312 205,182 218±18
Hemoglobin [g/dl] 9.5±0.5 8.8±0.4 10, 10.4 10.1±0.5 8.1±0.5 9.1, 9.2 8.5±0.5 7.3±0.4 7.1, 8.3 7.8, 7.1 6.5±0.3
Platelets [G/l] 360±32 316±32 269, 291 279±51 196±19 180, 201 228±31 129±6 122, 130 104, 180 117±11
Antithrombin III [%] 65±3 70±2 83, 78 53±3 55±4 59, 55 42±2 42±2 47, 42 30, 31 33±1
Nitrate/Nitrite
[μmol/l]
25.4±7.6 33.5±10.7 - 22.8±6.5 27.8±7.9 - 29.4±8.7 7.0±2.0 - 33.76, 76.15 5.5±1.6
BUN: blood urea nitrogen. ALP: alkaline phosphatase.*p<0.05 (difference between Hepa Wash and control).
A
l-C
halabiet
al.BM
C
G
astroenterology
2013,13:83
Page
7
of
10
http://w
w
w
.biom
edcentral.com
/1471-230X/13/83
Al-Chalabi et al. BMC Gastroenterology 2013, 13:83 Page 8 of 10
http://www.biomedcentral.com/1471-230X/13/83and severe hypotension during surgery by performing
side-to-side portacaval shunt instead prevents the devel-
opment of a multisystem organ failure at an earlier stage
and produces only a moderate elevation of ammonia.
Though cerebral edema is not a prominent feature of this
ALF model, it still corresponds to the clinical situation in
the majority of cases, where the overall incidence of clin-
ical cerebral edema in association with ALF appears to be
decreasing (less than 25%), while the incidence of multiple
organ failure as a mode of death is increasing [25,26].
Importantly, the ALF model used allows the evaluation
of liver support systems, especially with the elevated
levels of protein-bound and water-soluble toxins and the
presence of multiple organ failure. We noticed many
beneficial effects of the Hepa Wash in this model. Treat-
ment enhanced cardiovascular stability and prevented
the decline of cardiac index seen in the control group.
This stabilization of cardiac index could be due to the
removal of NO [27,28], which may lead to disturbances
of the myocardial contractility [29,30].
The use of invasive measurement of the cardiovascular
system (PiCCO System) helped us to eliminate differ-
ence in fluid balances as confounding factor. Early and
continuous adjustment of GEDI and ELWI in both
groups excludes volume depletion in the control group,
where further elevation of GEDI by fluid infusions would
worsen the already high ELWI values. Though they are
part of the standard medical therapy [19], we did not
use vasopressors in order to avoid the addition of a
confounding factor, that may make the interpretation of
the results more difficult.
The preserved urine production in the Hepa Wash
group might additionally have contributed to the lower
creatinine and BUN values, as these water soluble toxins
were also effectively eliminated by Hepa Wash. A criti-
cism to the design of the studies may emerge as the
medical management of control animals did not com-
prise hemodialysis. Hyperkalemia was treated success-
fully with insulin-glucose therapy. No hypoglycemia was
observed which could have been a confounding factor
for the worse outcome in the control group. The metabolic
acidosis was not severe enough to warrant hemodialysis.
Oliguria in the ALF model was the only clinical condition
which might have prompted the initiation of hemodialysis
but then the mean arterial pressure was already very low to
allow for treatment with extracorporeal procedures [31].
The improvement of the cerebral perfusion pressure in
the treatment groups was mainly due to amelioration of
the mean arterial pressure since the intracranial pressure
in the ALF animal model did not show rapid and severe
elevations. Therefore, cerebral perfusion pressure appears
to be a better parameter to assess the treatment effects.
These more pronounced effects on cerebral perfusion pres-
sure are supported by elimination of ammonia by HepaWash. In the animal studies on MARS and Prometheus
[21,22], the intracranial pressure was significantly reduced,
though no significant elimination of ammonia was found.
The lower levels of intracranial pressure in our ALF model
compared with the other models and the resultant diffi-
culty in showing significant differences may explain the dif-
ferent results.
The treatment with Hepa Wash may have improved
survival by supporting the detoxification function of the
liver and the kidney, thereby interrupting the vicious cycle
of elevated toxin level and the resultant worsening of mul-
tiple organ failure. Removal of liver disease-related toxins
like ammonia, creatinine, bilirubin and vasodilators may
reduce their toxic effects and improve the multiple organ
failure. We did not use scoring systems like SOFA or
MELD as they should be first validated in this animal
model (which is of a short duration). The use of surrogate
markers and mortality may obviate the use of scoring sys-
tems. Bilirubin elimination was not measured in the di-
alysate or filtrate, whereas the removed acid–base from
blood is difficult to accurately quantify due to the nature
of the procedure which involves adding strong acid and
base to the dialysate. However, the improvement of plas-
ma levels of these surrogate markers may support our
assumption of the good detoxification capacity of the
procedure.
The MARS system was able to improve the hemo-
dynamic instability before the sudden and severe eleva-
tion of intracranial pressure has ensued. Why this
elevation occurred only in the MARS animals and not in
the Hepa Wash group is not clear but it may be related to
the lower capacity of the procedure to remove ammonia
and the resultant cerebral edema. In any case, the results
are in line with the principle of limited available space and
the normal exponential pressure-volume relationship of
the cranium as described by Marmour et al. [32].
The authors believe that Hepa Wash could offer many
advantages over other artificial liver support systems. In
contrast to MARS or Prometheus where clearance of
toxins significantly declines after the first two hours due
to saturation of adsorbents or anion exchangers [33,34],
the Hepa Wash circuit has two conventional hemofilters
which represent the site for eliminating the toxins. The al-
bumin dialysate has an albumin concentration of 2% i.e.
one tenth the concentration of albumin in the MARS pro-
cedure (20%). The efficient removal of toxins through pas-
sage in the Hepa Wash circuit allows the conduct of the
dialysis procedure at higher flow rates than those used
routinely in the MARS or the SPAD procedures. In the
Hepa Wash procedure, the dialysate flow in the blood dia-
lyzer can be increased to 60 l/h in comparison to 1 l/h
in the SPAD procedure [5,6]. Plasma levels of different
medications including those that are protein bound may
be affected in this relatively non-selective elimination
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according to needs is required. Improved and consistent
detoxification of both protein-bound and water soluble
toxins were supported with safety aspects. The Hepa
Wash procedure did not cause adverse events and did not
result in bleeding despite the direct measurement of the
intracranial pressure and the presence of several fresh sur-
gical wounds like the laparotomy wound. The Hepa Wash,
however, substitutes only some of the liver and kidney de-
toxification functions without replacement of synthetic
functions which requires administration to the patient (e.g.
coagulation factors).
Conclusions
The authors admit that these are only preclinical results
with only a small sample size. We believe despite these
limitations that the preliminary animal data of biochem-
ical, organ function and survival improvement by the
Hepa Wash are encouraging. Providing an adequate liver
dialysis dose by increasing the capacity for the elimi-
nation of water-soluble and protein-bound toxins could
enhance the efficacy of artificial liver systems and halt
multisystem organ failure. Patients with ALF may show
an improvement of mortality if they were treated early
in the course of their illness with the new extracorporeal
procedure. Clinical studies appear to be justified.
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